268 filings
Page 2 of 14
8-K
nh5by6yvz cq
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
6hm66cec5
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
zpllik1 rbi
3 Oct 23
Departure of Directors or Certain Officers
4:31pm
8-K
2e1utr9kbro7iyhf
14 Aug 23
Other Events
8:00am
8-K
3d6cxrqty nfcg
10 Aug 23
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
7:03am
8-K
quy0frnn4f546 wkvxm0
25 Jul 23
Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024
7:02am
8-K
cou2m
17 Jul 23
Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer
4:08pm
8-K
dt1c r42v
1 Jun 23
June 2023 Larimar Therapeutics Corporate Presentation
4:06pm
8-K
dvc2e7u
15 May 23
Results of Operations and Financial Condition
7:05am
8-K
73ozm
12 May 23
Submission of Matters to a Vote of Security Holders
4:02pm
ARS
l9kwi 149b2rn
11 Apr 23
Annual report to shareholders
4:08pm
8-K
tvmjct5
6 Apr 23
Departure of Directors or Certain Officers
4:06pm
S-8
7h6 65gesv6a8slc8
14 Mar 23
Registration of securities for employees
5:16pm
S-8
ttb3e97d8v g5pqscprx
14 Mar 23
Registration of securities for employees
5:15pm
8-K
ymwgal6ddax70cd
14 Mar 23
Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results
7:32am